All posts by : Adherium
Adherium’s Smartinhaler selected for multisite study in EU
Melbourne, Australia-based smart inhaler company Adherium has been selected to supply the technology for a multi-country research program in Europe that will seek to establish whether home monitoring and mobile.
Meet Adherium at the British Thoracic Society Winter Meeting 2016, 7-9 Dec
Meet Adherium at the British Thoracic Society Winter Meeting 2016 7 to 9 December 2016 Location QEII Centre Broad Sanctuary Westminster London SW1P 3EE Exhibiting on stand 18 3rd floor,.
New Data Gives Adherium Fuel To Accelerate Digital Tech Adoption in Drug Sector
With nearly 40 published peer-reviewed journal articles under its belt, Adherium is hoping that the latest clinical data which underlines the ability of the company’s Smartinhaler to improve outcomes for.
Adherium’s Smartinhaler™ devices featured in 9NEWS story
Gabriella Rogers reports on a new combination treatment for asthma sufferers. Click here to watch the story.
Garth Sutherland to speak at Australia Biotech Invest
Chief Executive Officer and Co-founder, Garth Sutherland is scheduled to speak at the Australia Biotech Invest 2016 conference being to be held on 26-27 October, 2016 at the Melbourne Convention Centre, in.
Adherium’s Smartinhaler platform to be used by Astrazeneca for US COPD study
Melbourne, Australia, 13 June 2016: Adherium Limited (ASX: ADR), a global leader in digital health technologies that address sub- optimal medication use in chronic disease, today announced that AstraZeneca will.
Adherium Smartinhaler Technology in New Multinational Study
5,700 Adherium Smartinhaler™ devices plus associated software and communications technologies to be supplied through to 2018 Study in New Zealand, Australia, the United Kingdom & Italy Supply agreement with leading.
New Independent Data on Adherium Smartinhaler™ Clinical Outcomes Shows Increased Adherence and Reduction in Severe Attacks
September 30, 2015 – Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease; today announced that data from three independent.
Adherium digital health closes at 20% premium in ASX debut
August 26, 2015 – Digital health company Adherium Limited (ASX:ADR) ended its first day on the Australian Securities Exchange today with a closing price of 60 cents per share, a.
Adherium $35m ASX IPO to expand sales of digital health technology to improve medication adherence
August 5, 2015 – Australians and New Zealanders have an opportunity to invest in a highly promising digital health technology company that substantially improves medication adherence and patient health outcomes.